文献リスト

1) Calverley PM. Symptomatic bronchodilator treatment. In: Calverley PMA, Pride NB, editors. Chronic Obstructive Pulmonary Disease. London: Chapman and Hall; 1995. p.419-45

2) Barnes PJ. Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med. 1995; 152: 838-60

3) Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999; 115: 957-65

4) ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest. 2001; 119: 1661-70

5) Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002; 122: 47-55

6) Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008; 178: 332-8

7) Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2010; ― Available at: www.goldcopd.com (accessed June 2011)

8) Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res. 2010; 11: 149

9) Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002; 19: 209-16

10) Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008; 63: 831-8

11) Cote C, Pearle JL, Sharafkhaneh A, et al. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study. Pulm Pharmacol Ther. 2009; 22: 44-9

12) Partridge MR, Miravitlles M, Stahl E, et al. Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD. Eur Respir J. 2010; 36: 96-104

13) Tsagaraki V, Amfilochiou A, Markantonis SL. Evidence of tachyphylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients. Int J Clin Pract. 2006; 60: 415-21

14) Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010; 65: 473-9

15) Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest. 2002; 121: 1058-69

16) Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003; 22: 912-9

17) Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003; 21: 74-81

18) Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax. 2006; 61: 122-8

19) Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356: 775-89

20) Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest. 2008; 133: 1079-87

21) Baker WL, Baker EL, Coleman CI. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. Pharmacotherapy. 2009; 29: 891-905

22) Janssens W, VandenBrande P, Hardeman E, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008; 31: 78-83

23) Hochrainer D, Holz H, Kreher C, et al. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005; 18: 273-82

24) Battram C, Charlton SJ, Cuenoud B, et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5, 6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther. 2006; 317: 762-70

25) Bauwens O, Ninane V, Van de Maele B, et al. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin. 2009; 25: 463-70

26) Beier J, Chanez P, Martinot JB, et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther. 2007; 20: 740-9

27) Beier J, Beeh KM, Brookman L, et al. Broncho-dilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther. 2009; 22: 492-6

28) Naline E, Trifilieff A, Fairhurst RA, et al. Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. Eur Respir J. 2007; 29: 575-81

29) Sturton RG, Trifilieff A, Nicholson AG, et al. Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther. 2008; 324: 270-5

30) Lombardi D, Cuenoud B, Kramer SD. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties？ Eur J Pharm Sci. 2009; 38: 533-47

31) Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010; 182: 155-62

32) Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011; 37: 273-9

33) Kikkawa H, Kanno K, Ikezawa K. TA-2005, a novel, long-acting, and selective beta 2-adrenoceptor agonist: characterization of its in vivo bronchodilating action in guinea pigs and cats in comparison with other beta 2-agonists. Biol Pharm Bull. 1994; 17: 1047-52

34) Kanniess F, Make BJ, Petruzzelli S. Acute effect of carmoterol, a long-acting beta2-agonist, in patients with COPD [abstract]. Am J Respir Crit Care Med. 2008; 177: A655

35) Make BJ, Kanniess F, Bateman ED, et al. Efficacy of 3 different doses of carmoterol, a long-acting beta2-agonist in patients with COPD [abstract]. Am J Respir Crit Care Med. 2008; 177: A961

36) Rossing TH, Make BJ, Heyman ER. Carmeterol does not induce tolerance in COPD [abstract]. Am J Respir Crit Care Med. 2008; 177: A962

37) Tashkin DP, Kleerup EC, Heyman ER, et al. Effect of carmoterol pMDI on 24-hour FEV1 in COPD patients [abstract]. Eur Respir J. 2009; 34(Suppl 53): E4346

38) Linberg SE, Heyman ER, Nandeuil MA, et al. Cardiac safty of the novel very long-acting beta2-agonist carmoterol following single rising doses in healthy volunteers [abstract]. Eur Respir J. 2006; 28(Suppl 50): 665s

39) Bateman ED, Make BJ, Nandeuil MA. Safety and tolerability of a long-acting beta2-agonist in patients with COPD [abstract]. Am J Respir Crit Care Med. 2008; 177: A653

40) Bouyssou T, Casarosa P, Naline E, et al. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010; 334: 53-62

41) Bouyssou T, Hoenke C, Rudolf K, et al. Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy. Bioorg Med Chem Lett. 2010; 20: 1410-4

42) Rabe KF, Timmer W, Sagkriotis A, et al. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest. 2008; 134: 255-62

43) Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007; 146: 545-55

44) Singh D, Brooks J, Hagan G, et al. Superiority of “triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008; 63: 592-8

45) Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 180: 741-50

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp